Published in Ann Oncol on July 01, 2002
AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res (2010) 4.89
HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A (2004) 3.43
Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med (2008) 3.15
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol (2009) 2.71
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther (2011) 2.50
Molecular biomarker analyses using circulating tumor cells. PLoS One (2010) 2.38
Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol (2011) 2.29
Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer (2005) 2.02
Receptor conversion in distant breast cancer metastases. Breast Cancer Res (2010) 1.85
HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer (2004) 1.79
Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res (2007) 1.78
EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer. PLoS One (2015) 1.51
HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res (2007) 1.45
Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer (2008) 1.30
Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology (2011) 1.29
Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat Rev Clin Oncol (2014) 1.28
Detection of Cancer Metastases with a Dual-labeled Near-Infrared/Positron Emission Tomography Imaging Agent. Transl Oncol (2010) 1.26
The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp Mol Pathol (2009) 1.18
Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann Oncol (2009) 1.12
Treatment of HER2-positive breast cancer. Breast (2013) 1.09
HER-2/neu diagnostics in breast cancer. Breast Cancer Res (2007) 1.04
Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer. Clin Cancer Res (2014) 1.01
Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor. Oncologist (2012) 1.00
Stability of the HER2 gene after primary chemotherapy in advanced breast cancer. Virchows Arch (2005) 1.00
HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management? Br J Cancer (2007) 0.98
Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer. Hum Pathol (2010) 0.96
Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues. Front Oncol (2013) 0.95
HER2 expression in cervical cancer as a potential therapeutic target. BMC Cancer (2004) 0.94
Circulating tumor cells in breast cancer patients: an evolving role in patient prognosis and disease progression. Patholog Res Int (2011) 0.94
Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss. Virchows Arch (2011) 0.92
Assessment of progesterone receptors in breast carcinoma by PET with 21-18F-fluoro-16α,17α-[(R)-(1'-α-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione. J Nucl Med (2012) 0.92
Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. Breast Cancer Res (2014) 0.91
Assessment of a novel VEGF targeted agent using patient-derived tumor tissue xenograft models of colon carcinoma with lymphatic and hepatic metastases. PLoS One (2011) 0.90
Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer. Int J Clin Oncol (2013) 0.89
Challenges in the development of an autologous heat shock protein based anti-tumor vaccine. Hum Vaccin Immunother (2012) 0.88
Differences in radiosensitivity between three HER2 overexpressing cell lines. Eur J Nucl Med Mol Imaging (2008) 0.87
Trastuzumab therapy for the metastatic patient: does the primary match? Ann Oncol (2002) 0.84
Tumour heterogeneity and immune-modulation. Curr Opin Pharmacol (2013) 0.84
HER2/neu, Topoisomerase 2a, Estrogen and Progesterone Receptors: Discordance between Primary Breast Cancer and Metastatic Axillary Lymph Node in Expression and Amplification Characteristics. Breast Care (Basel) (2012) 0.83
A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation. J Transl Med (2015) 0.83
A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease. BMC Cancer (2012) 0.82
The importance of biopsy in clinically diagnosed metastatic lesions in patients with breast cancer. World J Surg Oncol (2014) 0.82
HER-2 Expression in Brain Metastases from Colorectal Cancer and Corresponding Primary Tumors: A Case Cohort Series. Int J Mol Sci (2013) 0.81
Extended trastuzumab therapy improves the survival of HER2-positive breast cancer patients following surgery and radiotherapy for brain metastases. Mol Clin Oncol (2013) 0.81
Comparison of Her-2, EGFR and cyclin D1 in primary breast cancer and paired metastatic lymph nodes: an immunohistochemical and chromogenic in situ hybridization study. J Korean Med Sci (2008) 0.81
The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. BMC Cancer (2015) 0.80
Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients? Biomark Cancer (2013) 0.80
Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases. Neuro Oncol (2015) 0.80
[Beyond staging, typing and grading. New challenges in breast cancer pathology]. Pathologe (2010) 0.80
HER2 as a novel therapeutic target for cervical cancer. Oncotarget (2015) 0.80
High Histologic Grade and High Ki-67 Expression Predict Phenotypic Alterations in Node Metastasis in Primary Breast Cancers. J Breast Cancer (2017) 0.79
Evaluation of immunohistochemistry and enzyme linked immunosorbent assay for HER-2/neu expression in breast carcinoma. Indian J Clin Biochem (2008) 0.79
Serum HER2 levels determined by two methods in patients with metastatic breast cancer. Int J Clin Oncol (2011) 0.78
Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging. Eur J Nucl Med Mol Imaging (2014) 0.77
Trastuzumab Administration in Patients with Metastatic Breast Cancer - Experience of a Large University Breast Center. Geburtshilfe Frauenheilkd (2014) 0.77
Concordance of c-kit mutational status in matched primary and metastatic cutaneous canine mast cell tumors at baseline. J Vet Intern Med (2013) 0.77
Comparison of immunophenotypes of primary breast carcinomas and multiple corresponding distant metastases: an autopsy study of 25 patients. Clin Exp Metastasis (2016) 0.77
Ileal metastasis of breast cancer in a patient with a BRCA2 gene mutation: report of a case. Surg Today (2011) 0.76
Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation. Int J Mol Sci (2016) 0.76
Predictive markers in primary breast cancer compared with lymph node and bloodspread metastases. Int J Physiol Pathophysiol Pharmacol (2009) 0.75
A FISH-based method for assessment of HER-2 amplification status in breast cancer circulating tumor cells following CellSearch isolation. Onco Targets Ther (2016) 0.75
Latest biopsy approach for suspected metastases in patients with breast cancer. Nat Rev Clin Oncol (2013) 0.75
Human epidermal growth factor receptor 2 protein expression between primary breast cancer and paired asynchronous local-regional recurrences. Exp Ther Med (2011) 0.75
Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry. Oncotarget (2017) 0.75
[Intratumoral heterogeneity of HER2 status in breast carcinoma]. Pathologe (2010) 0.75
Current Update of Patient-Derived Xenograft Model for Translational Breast Cancer Research. J Mammary Gland Biol Neoplasia (2017) 0.75
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet (2011) 8.24
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer (2007) 4.44
The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol (2000) 3.69
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer (2005) 3.40
Psychosocial correlates of oestrogen and progesterone receptors in breast cancer. Lancet (1990) 3.14
Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J (2001) 3.04
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2011) 2.80
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 2.66
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol (2003) 2.63
Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol (2000) 2.41
Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung Cancer (1998) 2.27
Virus C hepatitis and type 2 diabetes: a cohort study in southern Italy. Am J Gastroenterol (2013) 2.10
Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol (2005) 2.07
Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients. Clin Infect Dis (2001) 2.03
1st International consensus guidelines for advanced breast cancer (ABC 1). Breast (2012) 1.96
Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol (2006) 1.92
Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer (2005) 1.92
Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg (2003) 1.85
Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer (2004) 1.79
Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. Neurosurgery (1995) 1.72
Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol (2011) 1.71
Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol (2012) 1.69
Scoring systems in cancer patients admitted for an acute complication in a medical intensive care unit. Crit Care Med (2000) 1.69
Hemifacial spasm and arterial hypertension. Mov Disord (1999) 1.63
Risk factors for lymph node metastases and their prognostic significance in early gastric cancer (EGC) for the Italian Research Group for Gastric Cancer (IRGGC). Jpn J Clin Oncol (2001) 1.62
Super-extended (D3) lymphadenectomy in advanced gastric cancer. Eur J Surg Oncol (2010) 1.61
Insulin and gall stones: a population case control study in southern Italy. Gut (2000) 1.60
The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J (2002) 1.57
Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents (2007) 1.57
Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: distinct, overlapping or same populations. Oncogene (2011) 1.56
Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer (2003) 1.54
The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer (2002) 1.52
CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer (2004) 1.52
The bigger the better? ... or what we know and what we still need to learn about anthracycline dose per course, dose density and cumulative dose in the treatment of breast cancer. Ann Oncol (1997) 1.48
Possible involvement of androgen receptor alterations in hepatocarcinogenesis. Dig Liver Dis (2009) 1.48
Study on Ki-67 immunoreactivity as a prognostic indicator in patients with advanced gastric cancer. Jpn J Clin Oncol (1998) 1.48
Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol (2002) 1.46
Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer (2001) 1.44
Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activation. Breast (2004) 1.42
Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis. Lung Cancer (2002) 1.40
Disseminated tumour cells in bone marrow in experimental colon cancer: metastatic or resident? Colorectal Dis (2013) 1.40
K-ras and p53 mutations in DNA extracted from colonic epithelial cells exfoliated in faeces of patients with colorectal cancer. Dig Liver Dis (2000) 1.40
[EGF-R expression correlation between biopsy and surgical specimens of lung carcinoma]. Rev Mal Respir (2003) 1.39
EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol (1998) 1.39
Nuclear DNA content, proliferation index, and nuclear size determination in normal and cirrhotic liver, and in benign and malignant primary and metastatic hepatic tumors. Am J Clin Pathol (1993) 1.38
Belgian consensus guidelines for follow-up of women with cervical cytological abnormalities. Acta Clin Belg (2009) 1.38
Anti-basal ganglia antibodies in acute and persistent Sydenham's chorea. Neurology (2002) 1.38
Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother (1995) 1.31
A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer (2000) 1.27
A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis. Support Care Cancer (2000) 1.26
Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol (2001) 1.26
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol (2008) 1.24
Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries. Ann Oncol (2011) 1.24
High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. Ann Oncol (2014) 1.24
Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol (2001) 1.23
Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma. J Clin Pathol (2002) 1.22
Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst (1990) 1.22
BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol (2011) 1.20
Carbonic anhydrase IX antigen differentiates between preneoplastic malignant lesions in non-small cell lung carcinoma. Eur Respir J (1999) 1.20
Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol (2010) 1.20
Guidelines on the standards for the training of specialised health professionals dealing with breast cancer. Eur J Cancer (2007) 1.20
Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. Ann Oncol (2011) 1.19
The effects of a 24-h psychological training program on attitudes, communication skills and occupational stress in oncology: a randomised study. Eur J Cancer (1993) 1.18
Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol (1994) 1.16
Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol (1994) 1.16
The predictive value of HER2 in breast cancer. Oncology (2001) 1.15
Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. Aliment Pharmacol Ther (2004) 1.15
Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases. Am J Clin Pathol (2000) 1.15
The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer (2003) 1.14